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Abstract
IntroductIon: Presence of air in mediastinal space, retroperitoneal space or subcutaneously is a rare con-
dition in majority caused by trauma of airway or gastrointestinal (GI) tract. Rarely can it occur as a conse-
quence after drug usage.
cAse presentAtIon: We report a non-traumatic occurrence of pneumomediastinum, pneumoretroperito-
neum and subcutaneous emphysema in a 27 year-old male patient who had been inhaling mephedrone 
for 4 days. Patient was admitted to Department of General, Endocrine and Transplant Surgery, Medical 
University of Gdansk. CT scans of neck, chest and abdomen were performed with suspicion of perforation 
of GI tract or airways. Perforation was excluded by gastroscopic and bronchoscopic examinations. Patient 
was treated conservatively with fluids and antibiotic therapy because of no abnormalities besides free air 
in mentioned cavities. During 6 days of hospitalization patient made a steady recovery and was discharged 
in good condition.
conclusIons: The presence of pneumomediastinum, pneumoretroperitoneum and subcutaneous emphyse-
ma associated with mephedrone inhalation has been rarely reported in the literature in the past. There are 
only a few cases describing such complications and medical management required. By reporting this case 
we would like to emphasize that mentioned symptoms and history of drug use might seem life-threatening, 
however, this condition may be self-limiting as well. Therefore, good general state can potentially be indi-
cation for a watch-and-wait approach with no surgical intervention necessary.
Key words: spontaneous pneumomediastinum, pneumoretroperitoneum, subcutaneous emphysema, drug 
abuse, mephedrone
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IntroductIon
A presence of free air in mediastinal space (pneumo-
mediastinum) and in retroperitoneal space (pneu-
moretroperitoneum) can manifest as tachycardia 
and chest pain and may need prompt diagnostics 
and treatment. Trauma, foreign bodies and drug in-
toxication are some of the potential causes of these 
phenomena (Tab. 1, Tab. 2). The latter one most fre-
quently occur in young individuals, especially males 
[1]. Among vast variety of drugs that can lead to 
SPM (spontaneous pneumomediastinum) stimu-
lants, drugs such as cocaine are usually responsible 
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[2–3]. Mephedrone (4-methylmethcathinone) is rel-
atively new synthetic cathinone common in recre-
ational use [4]. It has stimulating effect similar to 
amphetamine (and derivatives) and cocaine. In this 
report we present a case of pneumomediastinum 
and pneumoretroperitoneum caused by mephed-
rone inhalation.
cAse presentAtIon
27-years old male was admitted to emergency de-
partment with agitation and impaired verbal and 
logical contact, tachycardia and tachypnoea, throat 
ache and high body temperature (39.5°C). Subcu-
taneous emphysema of neck and chest was noted 
upon physical examination (Fig. 1A). The following 
vital signs and laboratory results were recorded: 
heart rate 78 bpm, blood pressure 140/60, CRP 186, 
elevated PCT and glucose level. Empirical antibiotic 
therapy (ceftriaxone + clarithromycin, fluconazole) 
was administered and later changed to piperacil-
lin/tazobactam + metronidazole due to suspicion 
of GI perforation. Diagnostics were extended by 
neck, chest and abdomen contrast enhanced CT. 
Pneumomediastinum (Fig. 2A) and free air in both 
peritoneum and retroperitoneum were revealed (Fig. 
3A). Police report stated that patient was using un-
known drugs for past 4 days. 
InvestIgAtIon
Gastroscopy and bronchoscopy were performed to 
exclude the possible GI and airway perforation, how-
ever, no abnormalities were found. Initially, at admis-
sion, patient experienced delusions (i.e. delusions of 
reference, he believed that medical staff is working 
for the police). Normal verbal and logical contact 
was regained after 24 hours. After the patient re-
gained full consciousness detailed interview was pos-
sible — patient admitted to inhaling mephedrone. 
treAtment
The patient was treated medically. Antibiotic therapy 
and fluids were maintained during following 5 days 
of hospital stay. On the last day of hospitalization, 
Table 1. Potential causes of Pneumoretroperitoneum
CAUSES OF PNEUMORETROPERITONEUM MECHANISM
Disrupted alveoli Air migrates via the loosely packed paraesophageal 
connective tissue across the diaphragm
Inflammatory Bowel Disease
Inflammation → perforation
Perforation of a duodenal ulcer
Pneumatosis cystoids intestinalis
Necrotizing fasciitis
Abscess formation
Ruptured appendix
Foreign body 
Rupture of bowel wallIatrogenic (PEG placement, ERCP, laparoscopic operations, 
sigmoidoscopy, colonoscopy, epidural anesthesia, barium enema)
Table 2. Potential causes of Pneumomediastinum
CAUSES OF PNEUMOMEDIASTINUM MECHANISM
Chest trauma Increase of alveolar pressure → rupture of alveoli → 
releasing air → migration to the mediastinum through 
the peribronchial and perivascular sheaths 
Pulmonary disease (asthma, COPD, respiratory infections) Excessive coughing → rupture
Presence of foreign bodies in the airway, iatrogenic (artificial 
ventilation, bronchoscopy) Rupture of airways wall
Use of recreational drugs Inhalation → alveoli rupture
Childbirth, physical effort, excessive vomiting Valsalva’s maneuver
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a control CT of neck, chest, abdomen and pelvis was 
performed. The amount of free gas decreased in all 
locations (Fig.1–3B). 
follow-up And outcomes
Patient was discharged in good condition after 
6 days. No adverse and unanticipated events were 
observed. Patient was not present on follow-up visits.
dIscussIon
Pneumomediastinum, pneumoretroperitoneum and 
subcutaneous emphysema may be symptoms of ei-
ther GI tract or airway perforation. These conditions 
are potentially life threatening and may need sur-
gical intervention. However, as presented in this 
case they also may be rare and self-limiting compli-
cations of drugs inhalation, which can be treated 
medically under precise surveillance. Patients seek-
ing aid in emergency department because of SPM 
were usually admitted with sudden chest pain and 
dyspnea. Upon exclusion of tension pneumothorax, 
these symptoms require performing diagnostics to 
elucidate the reason for presence of free air in and 
outside of body cavities. As mentioned before GI 
tract and airway perforation are some of differential 
diagnoses and may need surgical intervention or 
fIgure 1. CT scan showing subcutaneous emphysema of neck — at diagnosis (A) and (B) before discharge
fIgure 2. CT scan showing pneumomediastinum — at diagnosis (A) and (B) before discharge
Disaster anD emergency meDicine Journal 2018, Vol. 3, No. 3
104 www.journals.viamedica.pl
chest drainage. Bronchoscopy, gastroscopy, colo-
noscopy and computed tomography can potentially 
exclude these pathologies. Once these diagnoses are 
excluded SPM may be diagnosed.
Drugs, including cocaine, met(amphetamine), 
MDMA, marihuana and, as presented, mephedrone 
may cause SPM and consequently pneumomedi-
astinum and subcutaneous emphysema [5, 6, 7, 8]. 
Probable explanation of development SPM as a re-
sult of inhalable drug use is that overly distended 
alveoli rupture under high pressure. Whenever the 
pressure gradient between the alveoli and the sur-
rounding interstitial space is sufficient the free air 
then dissects from the ruptured alveoli along the 
bronchovascular sheaths toward the mediastinum, 
to produce SPM. This sequence of events is known 
as the “Macklin effect” which is a result of Valsava’s 
maneuver [9]. Similar effect to Valsalva’s maneuver 
occurs in Muller’s maneuver in which chest pressure 
decreases in perialveolar spaces, and as a conse-
quence, air moves to hypothetic perialveolar space, 
without penetration of pleura [10]. Furthermore, 
most probable mechanism of pneumoretroperito-
neum occurrence is a translocation of free air form 
the chest to abdomen by aortic hiatus of the dia-
phragm. Subcutaneous emphysema is a rare condi-
tion that presents as a smooth bulging of the skin 
with a characteristic palpable crepitation. This can 
be traumatic, iatrogenic (puncture of the respiratory 
or GI tract) or spontaneous [11]. It can occur any-
where in the body but it is the most common in the 
head and neck region due to the proximity of the 
airways. Subcutaneous emphysema is not inherent-
ly life threatening and the air will be resorbed over 
time, but it can be uncomfortable for the patient. 
Mephedrone (4-methylmethcathinone) is a rel-
atively novel drug, with first reports of use from 
2007. Since then, its use is increasing, especially 
in Europe [12]. It is a synthetic cathinone that has 
never been licensed as a medicine and no other le-
gitimate uses are known. The effects and the mode 
of use have similarities with (meth)amphetamine, 
cocaine and 3,4-methylenedioxymethylampheta-
mine (MDMA), but its potency is lesser than (meth)
amphetamine [4]. Mephedrone can be administered 
via oral route, nasal insufflation, intramuscular injec-
tion, intravenous injection and rectal insertion. The 
predominant routes are oral ingestion and nasal 
insufflation [12]. The most common clinical features 
concerning mephedrone use are agitation, aggres-
sion, tachycardia, anxiety, confusion, psychosis and 
chest pain, however, it may also have no symptoms 
[2, 3]. Our patient presented majority of mentioned 
symptoms including rare ones such as SPM and re-
troperitoneum.
Most challenging obstacle in this case was the 
lack of knowledge on the type of substance that the 
patient was using. Impaired logical contact along 
with the fact that mephedrone does not come pos-
itive on the standard tox-screen delayed precise 
diagnosis. However, this was not crucial for the 
treatment, as endoscopic and radiologic examina-
tions confirmed SPM and along with good general 
condition enabled medical treatment. 
fIgure 3. CT scan showing pneumoretroperitoneum — at diagnosis (A) and (B) before discharge
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In conclusion, SPM caused by drug abuse usu-
ally is a benign condition which does not require 
surgical intervention nor chest drainage. Patient di-
agnosed with SPM that is in good general condition, 
with positive drug abuse history and no apparent 
perforation of airways or GI, should be treated con-
servatively.
LEARNING POINTS
1. Pneumoretroperitoneum is rare and usually benign 
complication of drugs inhalation 
2. SPM and pneumoretroperitoneum can be treated 
medically under precise surveillance
3. Self-resolution of these pathologies should be expected 
Source of funding — department funding.
Conflict of interest statement: Med. Stud. 
Perdyan. has nothing to disclose. Med. Stud. 
Piątkowska has nothing to disclose. Dr. Łaski has 
nothing to disclose. Dr. Spychalski has nothing to 
disclose. Prof. Łachiński has nothing to disclose.  
Dr. Kobiela has nothing to disclose.
REFERENCES
1. Graham R, Bowen N, Singh J. Mephedrone inhalation causes pneu-
momediastinum. BMJ Case Rep. 2014; 2014, doi: 10.1136/bcr-2014-
203704, indexed in Pubmed: 24614784.
2. Kouritas VK, Papagiannopoulos K, Lazaridis G, et al. Pneumomedi-
astinum. J Thorac Dis. 2015; 7(Suppl 1): S44–S49, doi: 10.3978/j.
issn.2072-1439.2015.01.11, indexed in Pubmed: 25774307.
3. James D, Adams RD, Spears R, et al. Clinical characteristics of 
mephedrone toxicity reported to the U.K. National Poisons Informa-
tion Service. Emerg Med J. 2011; 28(8): 686–689, doi: 10.1136/
emj.2010.096636, indexed in Pubmed: 20798084.
4. Best W, Bodenschatz C, Beran D. Mephedrone: Critical Review Report 
from the Expert Committee on Drug Dependence Thirty-sixth Meeting 
(Agenda item 4.12). World Health Organization. 2014: 1–34.
5. Rejali D, Glen P, Odom N. Pneumomediastinum following ecstasy 
(methylenedioxymetamphetamine, MDMA) ingestion in two people 
at the same ‚rave’. J Laryngol Otol. 2002; 116(1): 75–76, indexed in 
Pubmed: 11860664.
6. Kloss BT, Broton CE, Rodriguez E. Pneumomediastinum from nasal 
insufflation of cocaine. Int J Emerg Med. 2010; 3(4): 435–437, doi: 
10.1007/s12245-010-0205-9, indexed in Pubmed: 21373317.
7. Hazouard E, Koninck JC, Attucci S, et al. Pneumorachis and pneumo-
mediastinum caused by repeated Müller’s maneuvers: complications 
of marijuana smoking. Ann Emerg Med. 2001; 38(6): 694–697, doi: 
10.1067/mem.2001.118016, indexed in Pubmed: 11719752.
8. Albanese J, Gross C, Azab M, et al. Spontaneous pneumomediastinum: 
A rare complication of methamphetamine use. Respir Med Case Rep. 
2017; 21: 25–26, doi: 10.1016/j.rmcr.2017.03.007, indexed in 
Pubmed: 28348951.
9. Romero KJ, Trujillo MH. Spontaneous pneumomediastinum and subcu-
taneous emphysema in asthma exacerbation: The Macklin effect. Heart 
Lung. 2010; 39(5): 444–447, doi: 10.1016/j.hrtlng.2009.10.001, 
indexed in Pubmed: 20561891.
10. Maunder RJ, Pierson DJ, Hudson LD. Subcutaneous and mediastinal 
emphysema. Pathophysiology, diagnosis, and management. Arch 
Intern Med. 1984; 144(7): 1447–1453, indexed in Pubmed: 6375617.
11. Maan ZN, D’Souza AR. Spontaneous subcutaneous emphysema as-
sociated with mephedrone usage. Ann R Coll Surg Engl. 2012; 94(1): 
e38–e40, doi: 10.1308/003588412X13171221499108, indexed in 
Pubmed: 22524925.
12. EMCDDA. Report on the risk assessment of mephedrone in the 
framework of the Council Decision on new psychoactive substances. 
European Monitoring Centre for Drugs and Drug Addiction. Luxem-
bourg, Office for Official Publications of the European Communities. 
2011, doi: 10.2810/40800.
